Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

Review
. 2022 Aug 31;14(17):4232.
doi: 10.3390/cancers14174232.

V体育官网入口 - Novel Insights into miR-944 in Cancer

Jinze Shen  1 , Qurui Wang  1 , Chenhao Liang  1 , Xinming Su  1 , Yufei Ke  1 , Yunan Mao  1 , Jie Fang  1 , Shiwei Duan  1
Affiliations
Review

"V体育平台登录" Novel Insights into miR-944 in Cancer

Jinze Shen et al. Cancers (Basel). .

Abstract

miRNA is a class of endogenous short-chain non-coding RNAs consisting of about 22 nucleotides. miR-944 is located in the fourth intron of the TP63 gene in the 3q28 region. miR-944 is abnormally expressed in cancers in multiple systems including neural, endocrine, respiratory, reproductive, and digestive systems. miR-944 can target at least 27 protein-coding genes. miR-944 can regulate a series of cell behaviors, such as cell cycle, proliferation, invasion and migration, EMT, apoptosis, etc. miR-944 participates in the networks of 11 ceRNAs, including six circRNAs and five lncRNAs. miR-944 is involved in three signaling pathways. The abnormal expression of miR-944 is closely related to the clinicopathological conditions of various cancer patients. Deregulated expression of miR-944 is significantly associated with clinicopathology and prognosis in cancer patients VSports手机版. In addition, miR-944 is also associated with the development of DDP, RAPA, DOX, and PTX resistance in cancer cells. miR-944 is involved in the anticancer molecular mechanisms of matrine and Rhenium-liposome drugs. In conclusion, this work systematically summarizes the related findings of miR-944, which will provide potential hints for follow-up research on miR-944. .

Keywords: ceRNA; diagnosis; drug; dysregulation; miR-944; prognosis V体育安卓版. .

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pan-cancer analysis of miR-944 based on TCGA database. (A) Histogram of median quantile expression of miR-944 in non-tumor and tumor groups in the TCGA database. The blue font indicates that miR-944 is significantly low expressed in this cancer type; the red font indicates that miR-944 is significantly highly expressed in this cancer type; (B) comparison of miR-944 expression levels between non-tumor and tumor groups in the TCGA database. *** means p < 0.0000625; ** means p < 0.000625; * means p < 0.003125; ns means no significant difference; (C) overview of SNVs of TP63; (D) mutation types in TP63 protein domains in various cancers; (E) differences in the expression level of miR-944 between the TP63 mutant group (Mut) and the wild group (WT). Ns means no significant difference. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; STAD, stomach adenocarcinoma; SKCM, skin cutaneous melanoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
Figure 2
Figure 2
The correlation of miR-944 with TP63 CNV, TAp63, and ΔNp63. The figure indicates the position of hsa-mir-944 in the TP63 gene and shows the correlation of miR-944 with TP63 CNV and the expression of TAp63 and ΔNp63. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; STAD, stomach adenocarcinoma; SKCM, skin cutaneous melanoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma.
Figure 3
Figure 3
miR-944 and the regulation of cancer cell behaviors. miR-944 can regulate a variety of cancer cell biological behaviors through its ceRNA networks or target genes.
Figure 4
Figure 4
The ceRNA networks of miR-944. The ceRNA networks of miR-944 involve 11 ceRNAs and 27 protein-coding genes. It can regulate a variety of cancer cell biological behaviors, such as proliferation, invasion, migration, apoptosis, drug resistance, EMT, growth, and cell cycle in 16 cancers.
Figure 5
Figure 5
Exogenous factors and drugs affect the level of miR-944. (A) miR-944 is involved in the treatment of NSCLC and HNSCC by matrine and 188Re-liposome, respectively; (B) exogenous factors (including NNK, HPV E6/E7, and alcohol and acetaldehyde) affect the expression level of miR-944 in the OSCC, CxCa, and HCC.
Figure 6
Figure 6
“↑”: activation of the signaling pathway will promote the cell behavior; “↓”: activation of the signaling pathway will inhibit the cell behavior. miR-944 is involved in the regulation of three signaling pathways. miR-944 plays a regulatory role in the occurrence and development of cancer by participating in the Wnt/β-catenin, PI3K/AKT, and Jak/STAT signaling pathways.
Figure 7
Figure 7
The miR-944-related therapeutic drugs. (A) miR-944 is associated with resistance to 4 drugs (DDP, RAPA, DOX, and PTX); (B) the target drugs of miR-944′s PCGs and the ceRNA/miR-944/PCG axes in the CADDIE database.
See this image and copyright information in PMC

References

    1. Ha M., Kim V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014;15:509–524. doi: 10.1038/nrm3838. - "VSports" DOI - PubMed
    1. Lee H.Y., Han S.S., Rhee H., Park J.H., Lee J.S., Oh Y.M., Choi S.S., Shin S.H., Kim W.J. Differential expression of microRNAs and their target genes in non-small-cell lung cancer. Mol. Med. Rep. 2015;11:2034–2040. doi: 10.3892/mmr.2014.2890. - "VSports注册入口" DOI - PubMed
    1. Pereira T., Brito J.A.R., Guimaraes A.L.S., Gomes C.C., de Lacerda J.C.T., de Castro W.H., Coimbra R.S., Diniz M.G., Gomez R.S. MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma. J. Oral Pathol. Med. 2018;47:78–85. doi: 10.1111/jop.12650. - DOI - PubMed
    1. Zou Y., Zhong C., Hu Z., Duan S. MiR-873-5p: A Potential Molecular Marker for Cancer Diagnosis and Prognosis. Front. Oncol. 2021;11:743701. doi: 10.3389/fonc.2021.743701. - DOI - PMC - PubMed
    1. Park S., Kim J., Eom K., Oh S., Kim S., Kim G., Ahn S., Park K.H., Chung D., Lee H. microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer. BMC Cancer. 2019;19:419. doi: 10.1186/s12885-019-5620-6. - DOI - PMC - PubMed

Publication types

LinkOut - more resources